Διαγνωστική και θεραπευτική προσέγγιση IPF

Transcript

1 «Εξ ἐλαχίστων καὶ ἁπλουστάτων ὑποθέσεων δεικνύναι τὰ ζητούμενα». Πυθαγόρας ( πχ) Διαγνωστική και θεραπευτική προσέγγιση IPF Thinking outside the box-purus Interstitius Purus Asinus Αργύριος Τζουβελέκης Biomedical Sciences Research Center Alexander Fleming PCCSM Yale School of Medicine Interstitial Lung Disease Unit, SOTIRIA Hospital, University of Athens

2 Δεδομένα

3 Ιδιοπαθής Πνευμονική Ίνωση 3+1 major characteristics

4 1.Unknown Unknownpathogenesis pathogenesis Alveolar physiological state Recurring microinjuries Epithelial cells apoptosis Pneumocyte type I Usual Interstitial Pneumonia Lesion Epithelial & fibroblast activation Pneumocyte type II Matrix remodeling Endothelial cell Cell proliferation and migration Fibroblast

5 2. Highly unpredictable clinical course Slow progressors Rapid progressors Acute exacerbations Ley et al. AJRCCM 2011;183:

6 Deposition Other exposure Fibroblast Matrix Environment Infection/Biome Telomere Degradation Mitochondria Cigarette Smoke Environment Aging Mitochondria MUC5B Epithelial Injury Progenitor Epithelial Injury Cancer Aging Development Not a single disease!! Innate PH Accelerated Burnt-Out Immunity Adaptive Vascular Comorbidities Activity Stable

7 Lethal Disease 3. Lethal disease

8 4. Aging disease

9 Aging governs wound-healing response Aging-time-dependent functional decline of organs and tissues Senescence-irreversible cease of cell division Leading cause of death in Western civilization 100/150 K people across the globe die every day of age-related causes IPF incidence 10/ IPF incidence >65 yrs 90/

10 One size does not fit all. CHRONIC WITHOUT SYSTEMIC DISEASE (Idiopathic interstitial Pneumonias, CEP,LAM Alv proteinosis, PVOD) CHRONIC WITH SYSTEMIC DISEASE (vasculitis, CVD Sarcoidosis) ACUTE (AIP, AEP, HP) ILD >500 SUBACUTE (COP, HP) EPISODIC (HP, vasculitis, COP, EOS. PNEUMONIA) CHRONIC KNOWN ETIOLOGY (Environmental, Occupational, Drugs)

11 Estimated Relative Distribution of Specific ILDs in the US NEJM 2018

12 AJRCCM 2013 Idiopathic interstitial pneumonias (IIP) Idiopathic pulmonary fibrosis/usual interstitial pneumonia (IPF/UIP) Nonspecific interstitial pneumonia (NSIP) Cryptogenic organizing pneumonia (COP/OP) Desquamative interstitial pneumonia (DIP) Respiratory bronchiolitisassociated interstitial lung disease (RBILD) Acute interstitial Pneumonia (AIP) RARE IIPs 55% 25% 3% 15% 3%

13 Current Definition of IPF Distinct chronic progressive fibrosing interstitial pneumonia of unknown cause, primarily occurring in older adults, is limited to the lungs, and has typical imaging and pathologic findings of UIP ATS/ERS/JRS/ALAT Statement. Am J Respir Crit Care Med. 2011;183:

14 Διάγνωση

15

16 ATS/ERS 2011 Fleischner 2018 ATS/ERS 2018

17 Ιστορικό Κλινική εξέταση

18 DIAGNOSTIC APPROACH OF IIPs History, physical exam, serology, PFTs, CXR NOT IIP e.g, CTD-ILD, drug-induced ILD, environmental ILD. POSSIBLE IIP HRCT Definite IPF in HRCT with compatible clinical picture Atypical clinical or HRCT picture Findings diagnostics of other ILD, e.g., Histiocytosis. Suspicion of other ILD TBB /BAL? NON DIAGNOSTIC TBB, BAL or other exam Surgical biopsy UIP NSIP RB-ILD DIP AIP COP RARE Nonclassified 18

19 HISTORY AGE (>50 years) GENDER (male>female) SMOKING (frequently) DRUGS (exclude) Sx DURATION (months-years) EXPOSURE (organic/inorganic dust) FAMILIAL PULMONARY FIBROSIS (5-8%)

20 Drugs eg, Amiodarone, bleomycin, nitrofurantoin Radiation External beam radiation therapy to thorax Connective Tissue Diseases Rheumatoid arthritis Systemic sclerosis (scleroderma) Idiopathic inflammatory myopathies Vasculitis Known Causes of ILD: History & Physical Exam Occupational/Environmental Inorganic antigens (Pneumoconioses) Asbestosis Coal worker s pneumoconiosis Silicosis Organic antigens (Hypersensitivity Pneumonitis) Birds Mold

22

23 Fine end inspiratory basal crackles (velcro).

24 Ανοσολογικό Προφίλ

26 Serologic Tests Can Help Identify Other Conditions

27 Serologic Tests Can Help Identify Other Conditions ATS/ERS/JRS/ALAT Statement. Am J Respir Crit Care Med. 2018;183: Connective tissue diseases ANA, RF & anti-ccp (ERS/ATS guidelines) CK and aldolase Anti-myositis panel with Jo-1 antibody ENA panel Scl-70, ACA Ro (SSA), La (SSB) MPO/PR3 (ANCA) Smith, RNP ESR, CRP Hypersensitivity pneumonitis Hypersensitivity panel (if exposure history)

28 Ακτινολογικό Πρότυπο

29

30 HRCT Criteria for UIP ATS/ERS PATTERNS ATS/ERS PATTERNS Raghu G, et al. Am J Respir Crit Care Med. 2011;183:

31 Predominance DEFINITE UIP PATTERN ATS/ERS 2011 ATS/ERS 2018 Distribution HCM More flexible

32 POSSIBLE BECAME PROBABLE ATS/ERS 2011 ATS/ERS 2018 No HCM

33 Probable UIP pattern requires biopsy or not? Raghu G, et al. Eur Respir J. 2018;52:

34 HRCT Criteria for UIP ATS/ERS 2011 ATS/ERS 2018 Raghu G, et al. Am J Respir Crit Care Med. 2011;183:

35 Indeterminate Pattern Familial IPAF Unclassifiable Early UIP pattern Truly indeterminate

36 RARE >30% UNCLASSIFIABLE

37 Inconsistent with UIP/Pointing to another Dx ATS/ERS 2011 ATS/ERS 2018 Raghu G, et al. Am J Respir Crit Care Med. 2011;183: Raghu G, et al. Am J Respir Crit Care Med. 2018;198:e44-68.

38 Παθολογοανατομικό πρότυπο

39 HRCT Criteria for UIP ATS/ERS 2011 ATS/ERS 2018

40 Fibrosis + Subpleural+ Heterogeneity + FF

41 USUAL INTERSTITIAL PNEUMONIA AND IDIOPATHIC PULMONARY FIBROSIS LIP AIP KNOWN ETIOLOGY CVD-PF, DRUGS, HP, Asbestosis etc RB-ILD DIP UIP-IPF COP NSIP Most UIPs are IPF, ALL UIPs ARE NOT IPF Slide courtesy of Demosthenes Bouros

42 Διαγνωστικές Παρεμβάσεις

43 Diagnostic Interventions 1. Bronchoalveolar lavage cellular analysis 2. Surgical lung biopsy 3. Transbronchial lung biopsy 4. Transbronchial lung cryobiopsy 5. Multidisciplinary discussion 6. Serum biomarkers

44 ATS/ERS 2011 Vote: 4 for the use of BAL, 18 against the use of BAL, 1 abstention, 8 absent.)

45 50% of chp patients were misdiagnosed as IPF BAL provides us vital information on degree of alveolitis treatment response

46 Summary of recommendations Upgrade of BAL, HRCT and pre-test clinical probability We suggest cellular analysis of BAL We suggest SLB We suggest MDD No recommendation for TBBx No recommendation for SLB Probable + Indeterminate + Alternative pattern

47

48 Approach to the Diagnosis of IPF Clinical History Physical Laboratory PFTs Radiology Chest X-ray HRCT Pathology Surgical lung biopsy Primary care physicians Pneumonologist Radiologist Pathologist Multidisciplinary discussion GOLD STANDARD REFERENCE CENTER

49 Θεραπεία

50 Management Disease + Acute Exacerbations Comorbidities QoL Palliative care

51 Θεραπεία IPF Until adequate studies are conducted combined therapy : corticosteroid The art of medicine consists of amusing the patient, while the nature cures the disease. Voltaire azathioprine or cyclophosphamide NOT BASED ON SCIENTIFIC DATA EXPERT OPINION, LOW EVIDENCE! MICO- Masterful Inactivity with Cat-like Observation Athol Wells 2008 ATS / ERS consensus statement, AJRCCM 2000;161:646

52 Probability PANTHER-IPF: prednisone, azathioprine, N-acetylcysteine: A study that evaluates response in IPF Probability Probability Time to death Triple therapy Placebo Time to death or disease progression Triple therapy Anno Mirabilis Placebo Time to death or hospitalisation Triple therapy Placebo Idiopathic Pulmonary Fibrosis Clinical Research Network. N Engl J Med 2012;366:

53 Μηχανισμοί δράσης πιρφενιδόνης Αντι-ινωτικό Άγνωστος ακριβής μηχανισμός δράσης Ενεργό σε πολλαπλά θεραπευτικά μοντέλα ίνωσης TNF-α IL-6 TGF-β IL-6 Pirfenidone Collagen MMPs Collagenase s ROIs Hilberg O, et al. Clin Respir J. 2012;6:

54 Pirfenidone reduces annual rate of FVC decline in 1247 patients from three phase III RCTs Noble et al. Eur Respir J. May 2016

55 Μακροχρόνιο προφίλ ασφάλειας και αποτελεσματικότητας

56 Μηχανισμοί δράσης nintedanib Αναστολέας τυροσινικών κινασών Ενεργοποιητής φωσφατασών Αντι-καρκινικό VEGF Nintedanib PDGF FGF SHP-1 Pleiotropic Effects Hilberg F, et al. Cancer Res. 2008;68(12): Tai WT, et al. J Hepatol. 2014;61(1):89-97.

57 NINTEDANIB-INPULSIS TRIALS Primary efficacy endpoint in pooled data Adjusted annual rate (SE) of decline in FVC (ml/year) Mean (SE) observed change from baseline in FVC (ml) 0-50 Nintedanib 150 mg bid Placebo , 6-223, ml/year 5 (95% CI: 75.9, 144.0) p< Nintedanib 150 mg bid (n=638) Placebo (n=423) No. of patients Nintedanib Placebo Week Richeldi et al. NEJM 2014; 370:

58 734 patients (59% continued- 41% initiated ND) No additional safety signals Acceptable cardiovascular profile Similar efficacy effects BUT

59 Αντι-ινωτικά Καθημερινοί Προβληματισμοί Pirfenidone 9 χάπια/day συνοσηρότητες? 3 χάπια/day-σκεύασμα Pirfenidone φωτοευαισθησία (Μεσογειακή χώρα) Nintedanib διάρροιες αντι-διαρροϊκά (λοπεραμιδη) και τιτλοποιηση δόσης- 100 mg/day αποτελεσματικό? Nintedanib επιφυλακτικοί με Στεφανιαία νόσο (30%) Επιλογή φαρμάκου κατόπιν συζήτησης με τον ασθενή

60 Need for new treatments 1. High screening failure 65% pirfenidone 35% nintedanib trials 2. Treatment for all phenotypes and endotypes - Personalized medicine 3. Treatment for AEx and comorbidities 4. Less side effects clinical trials in IPF since 2000, 145 articles on novel drugs Tzouvelekis A et al. Curr Opin Pulm Med 2017

61 Νεότερες κλινικές μελέτες στην IPF PHASE I MACITENTAN PRM-151 ILOPROST BOSENTAN STX-100 hmsc AMBRISENTAN ETANERCEPT IMATINIB PHASE II PHASE III REGISTRATION LAUNCHED NINTEDANIB Pirfenidone (Esbriet ) TD139 CC-930 GSK CNTO 888 SAR CO-TRIMOXAZOLE OMEPRAZOLE GLPG1690 NAC QAX576 LOSARTAN POSITIVE RESULTS NEGATIVE RESULTS ZILEUTON THALIDOMIDE WARFARIN TREPROSTINIL TETRATHIOMOLYBDATE TRIPLE THERAPY SILDENAFIL BMS SIMTUZUMAB OCTREOTIDE TRALOKINUMAB IFN-g GC1008 LEBRIKIZUMAB FG-3019 IW001 ONGOING PENDING RESULTS N>180

62 Combination clinical trials Agent Clinical Trials.gov registry number 1. Pirfenidone - NAC PANORAMA study Lancet RM-2016 Study design Endpoints Outcome Phase 4 Safety Well tolerable-mild photosensitivity enhancement in NAC group 2. Pirfenidone + Nintedanib NCT Phase 4, Open label, Non- Randomized, Single group 3. Pirfenidone + Nintedanib NCT Phase 4, Open label, Non- Randomized, Multiple-dose, Two group Safety and Tolerability Pirfenidone-nintedanib low risk, high synergy 4. Pirfenidone + Sildenafil NCT Phase 2, Randomized, Placebocontrolled Interaction in Pharmacokinetics Efficacy, safety, and tolerability Ongoing Ongoing Ongoing 5. Pirfenidone + Vismodegib NCT Phase 1, Open label, Single group 6. Pirfenidone + Lebrikizumab NCT Phase 2, Randomized, Placebocontrolled 7. Nintedanib + Sildenafil NCT Phase 2, Randomized, Placebocontrolled Safety, and tolerability Efficacy and safety Efficacy and safety Ongoing Ongoing Ongoing

63 Management Disease + Acute Exacerbations Comorbidities QoL Palliative care

64 IPF Acute exacerbations

65 Total (n=509) % Europe (n=238) % North- America (n=56) % South- America (n=51) % Asia (n=115) % Methylpredni 500mg with 62 tapering Methylpredni 500mg pulsed (w/o tapering) Prednisolon 100 mg No immunsuppression CsA Cyclophosphamide i.v Tacrolimus Rituximab Australia (n=25) % Differences between continents: p <

66 Always antibiotics incl. macrolides* Total (n=509) % Europe (n=238) % North-America (n=56) % South-America (n=51) % Asia (n=115) % Antibiotics only in infection* Polymyxin B Hemoperfusion Thrombomodulin , Plasmapheresis Always initiate antacids Continue current antifibrotic Switch antifibrotic Discontinue any antifibrotic Australia (n=25) % Differences between continents: p = 0.43*; p=<

67

68 Treatment-IPF Acute exacerbations Best supportive care Oxygen Broad spectrum antibiotics (piperacillin-tazobactam, meropenem) Antiviral LMWH Diuretics NIV (selective cases) MDD-On an individual case basis Prevention is the key Anti-fibrotics Rx of CoM - Vaccination

69 IPF and comorbidities IPF and emphysema CPFE (30-60%) IPF and Pulmonary Hypertension (10-80%) IPF and metabolic disorders (diabetes-hypothyroidism-40%) IPF and Lung cancer (15%) IPF and GERD (80%) IPF and sleep apnea (6-10%) IPF and ischemic heart disease (30%) IPF and depression (25%) Raghu et al. Eur Respir J ;46:

70 Thinking outside the box

71 Thinking outside the box

72 406 patients 274 randomized (32% screening failure) Nintedanib 150 mg (bid) + Sildenafil 20 mg (tid)/placebo (1:1) No difference in SGRQ (primary end-point) No difference in UCSD dyspnea score (primary end-point Negative study. BUT..

73 Subgroup Analysis

74 DO NOT DILATE REMODELLED VESSELS!!!! Worsens V/Q MISMATCH Major Clinical trials in Patients with IPF-PH Therapy Study Year Study population Duration Primary end point Result Bosentan BUILD IPF-158 (1/1) 52 weeks Bosentan BUILD IPF-616 (2/1) 52 weeks 6MWD Time to IPF worsening or death Negative Do not dilate remodeled vessels!! Negative Bosentan Worsens B-PHIT 2014 V/Q Fibrotic IIP-60 mismatch (2/1) 16 Decrease w/o in CO Negative weeks Macitentan MUSIC 2013 IPF-178 (2/1) 52 weeks %change in FVC Negative improvement Ambrisentan ARTEMIS 2013 IPF-492 (75%) (2/1) n/a Time to IPF disease progression Sildenafil STEP 2010 Adv. IPF-180 (1/1) 12 weeks Riociguat RISE-IIP 2017 Major IIPs 26 weeks 6MWD 20% 6MWD Early termination Negative Early termination

75 IPF and comorbidities IPF and emphysema CPFE (30-60%) IPF and Pulmonary Hypertension (10-80%) IPF and metabolic disorders (diabetes-hypothyroidism-40%) IPF and Lung cancer (15%) IPF and GERD (80%) IPF and sleep apnea (6-10%) IPF and ischemic heart disease (30%) IPF and depression (25%) Raghu et al. Eur Respir J ;46:

76 HRCT/PET-early dx IPF severity/tnm Avoid irradiation Beware of surgical interventions +chemo Don t discontinue antifibrotics

77 Περιστατικό ο 1

78 Ιστορικό Παρούσα Νόσος Άνδρας, 60 ετών, 0p/yrs, έκθεση σε καναρίνια (>5 ετη) Προιούσα δύσπνοια (DOE II/IV) ξηρός βήχας Α/Ε: SaO2: 96%-FiO2: 21%, HR: 75bpm, clubbing (-/-), ΜΜΡ +/+,κφ κατά τα λοιπά συστήματα Δεν αναφέρει Raynaud, αρθραλγίες, μυαλγίες, πρωινή δυσκαμψία Σπιρομέτρηση: FVC: 68%, Tif: 75.6, TLC: 48%, DLCO:31% 6MWD: 390m, 95% (start) 86% (end) HRCT

79

80 Ποιο το ακτινολογικό πρότυπο Definite UIP Probable UIP Indeterminate Alternative diagnosis

81 Επόμενο βήμα Βρογχοσκόπηση Bιοψία Βρογχοσκόπηση και ανοσολογικός έλεγχος Παρακολούθηση και επανέλεγχος σε 6 μήνες

82 BAL-serology Βρογχοσκόπηση: MΦ: 52%, Λεμφοκύτταρα:44%, Εωσινόφιλα:3%, Πολυμορφοπύρηνα: 1% Ανοσολογικός έλεγχος: ΑΝΑ:1/80, Ra test, ENA panel: negative

83 Θα χρειαστεί βιοψία? Ναι Όχι

84 Καταλληλότερη θεραπεία Υψηλές δόσεις κορτικοστεροειδών (>20mg) και αζαθειοπρινη Χαμηλές δόσεις κορτικοστεροειδών (10-15mg) + ανοσοτροποποιηση (MMF) Αντι-ινωτικό Παρακολούθηση

85 Περιστατικό ο 2

86 Ιστορικό Παρούσα Νόσος Άνδρας, 60 ετών, <5p/yrs, 180 cm, 90kg 2007: Ιδιοπαθής Υπερασβεστουρία- chlorothalidone 2007: Θυρεοειδίτιδα Hashimoto 02/01/2017: Μη παραγωγικός βήχας δύσπνοια προσπαθείας (ΙΙ/ΙV), από 6μήνο-δεκατική πυρετική κίνηση από 3ημέρου-ιδιώτης πνευμονολόγος Eργαστηριακές εξετάσεις: Hct: 47.1, Hgb: 14.1, WBCs: , CRP: 3.4 Aκτινογραφία θώρακος Moxifloxacin-7d Α/Ε: SaO2: 96%-FiO2: 21%, HR: 75bpm, clubbing (-/-), ΜΜΡ +/+,κφ κατά τα λοιπά συστήματα Aναφέρει Raynaud, xωρίς αρθραλγίες, μυαλγίες, πρωινή δυσκαμψία Σπιρομέτρηση: FVC: 73%, Tif: 81.6, TLC: 48%, DLCO:39% 6MWD: 410m, 98% (start) 88% (end) HRCT

87 HRCT-Ιανουάριος 2017

90 Ποιο το ακτινολογικό πρότυπο Definite UIP Probable UIP Indeterminate Alternative diagnosis

91 Επόμενο βήμα Βρογχοσκόπηση Ανοσολογικός έλεγχος Βρογχοσκόπηση και ανοσολογικός έλεγχος Παρακολούθηση και επανέλεγχος σε 6 μήνες

92 Φεβρουάριος 2017 Βρογχοσκόπηση: MΦ: 52%, Λεμφοκύτταρα:37%, Εωσινόφιλα:8%, Πολυμορφοπύρηνα: 3% Ανοσολογικός έλεγχος: ΑΝΑ:1/640, Ra test, ENA panel: negative

93 Επόμενο βήμα VATS-Βιοψία Πνεύμονος Cryobiopsy TBB Έναρξη θεραπείας

94 VATS

95 IPAF UIP-HCM

96 Ευχαριστώ πολύ